Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres